Novel Purification Technologies and Approaches to Maximize Speed, Efficiency and Process Optimization

Over the past several years, significant progress has been made to increase upstream process titers, thus creating a strain on existing downstream purification technologies. Although implementation of continuous unit operations has provided some relief, downstream processing still presents a major bottleneck in the production of therapeutic antibodies.

In this presentation, we will demonstrate an integrated downstream purification process to enable significant removal of critical impurities. Through use of an affinity chromatography that possesses high dynamic binding capacities of greater than 60 g/L, we have obtained antibodies with increased purity while reducing overall process time.

Furthermore, by using select additives during process chromatography, we demonstrate this process can be fine-tuned to enhance target antibody selectivity by removing host cell protein impurities and aggregates. When used in conjunction these technologies represent a highly efficient process to obtain monoclonal antibodies for use as therapeutics.

This presentation was given during Bioprocess International and Cell & Gene Therapy Asia Digital Week, April 5 - 8, 2021.

Presented by:

Jungmin Oh, Manager - New Product Development In her current role, Jungmin leads product and process development projects focusing on solving customer-centric problems with multiple biopharmaceutical industry partners. Collaborations include optimization of the downstream purification process through application of J.T Baker chromatography products. She holds a MS and Ph.D. in chemical engineering, specializing in the optimization of a continuous chromatography system.